Gufic BioSciences has been assigned an overall Environmental, Social and Governance (ESG) rating of CRISIL ESG 62, categorized as "Strong," for FY26. The assessment was conducted by Crisil ESG Ratings & Analytics Ltd, a SEBI-registered Category-I ESG rating provider.

The rating was issued in a report dated September 25, 2026, which the company received on September 28, 2026. This disclosure was made pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Independent Assessment Methodology

A key distinction in this disclosure is that Gufic BioSciences did not engage Crisil for the ESG rating. Instead, Crisil independently assigned the rating based solely on information pertaining to FY26 that was available in the public domain. This approach ensures the evaluation reflects externally verifiable data rather than company-supplied metrics.

Rating Details

The company confirmed the receipt of the intimation to both BSE Limited and National Stock Exchange of India Limited. The disclosure was signed by Ami Shah, Company Secretary & Compliance Officer.

Gufic Biosciences Limited must pay a ₹1,72,000 penalty to the National Stock Exchange (NSE) by October 3, 2026, after the exchange rejected its waiver application.

The fine relates to non-compliance with SEBI listing regulations concerning the appointment of Kamal Kishore Seth as an Additional Director. Seth, aged over 75, was appointed without the required shareholder approval via special resolution for the quarter ended September 30, 2024.

Regulatory Context and Prior Actions

The company had previously paid a separate penalty of ₹8,000 to both BSE and NSE for similar non-compliance in the quarter ended June 30, 2024. Subsequently, Gufic filed waiver applications with both exchanges to contest these fines.

BSE rejected Gufic’s waiver application earlier, with the decision communicated on March 13, 2026. The recent NSE rejection confirms that the regulatory stance remains firm across both exchanges regarding the appointment of directors exceeding the age limit without specific shareholder consent.

Compliance Timeline

The sequence of regulatory actions highlights the company's ongoing compliance challenges:

What the Numbers Show

The total financial impact of this specific governance lapse amounts to ₹1,80,000 when combining the already-paid June quarter penalty (₹8,000) and the newly mandated September quarter penalty (₹1,72,000). The significant disparity between the two quarterly penalties suggests that the NSE may have assessed the severity or duration of the non-compliance differently across quarters, or applied distinct fee structures for repeated violations within the same fiscal period.